@article{
 title = {Reduced functional bladder capacity associated with ketamine use},
 type = {article},
 year = {2019},
 identifiers = {[object Object]},
 pages = {270-271},
 volume = {41},
 websites = {http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462019000300270&tlng=en},
 month = {5},
 publisher = {Associação Brasileira de Psiquiatria},
 id = {76bf86c0-ac38-361c-9a9c-2fa053c6fb62},
 created = {2019-06-23T11:24:23.770Z},
 accessed = {2019-06-18},
 file_attached = {false},
 profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},
 group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
 last_modified = {2019-06-23T11:24:23.770Z},
 tags = {Disc:Pharmacology,OA},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {false},
 hidden = {false},
 private_publication = {false},
 abstract = {Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a dissociative anesthetic with sedative and analgesic effects that was developed in the 1960s for human and veterinary medicine. More recently, ketamine has been used to treat severe, refractory depression when pharmacotherapy and electroconvulsive therapy are not effective.1,2 In addition, ketamine is also consumed as drug of abuse, potentially leading to serious and irreversible complications.},
 bibtype = {article},
 author = {Ramos, Sergio de P. and Zambonato, Tatiana K. and Graziottin, Túlio M. and Ramos, Sergio de P. and Zambonato, Tatiana K. and Graziottin, Túlio M.},
 journal = {Brazilian Journal of Psychiatry},
 number = {3}
}

{"_id":"LyuTKFkaGSmutseQ5","bibbaseid":"ramos-zambonato-graziottin-ramos-zambonato-graziottin-reducedfunctionalbladdercapacityassociatedwithketamineuse-2019","authorIDs":[],"author_short":["Ramos, S., d., P.","Zambonato, T., K.","Graziottin, T., M.","Ramos, S., d., P.","Zambonato, T., K.","Graziottin, T., M."],"bibdata":{"title":"Reduced functional bladder capacity associated with ketamine use","type":"article","year":"2019","identifiers":"[object Object]","pages":"270-271","volume":"41","websites":"http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462019000300270&tlng=en","month":"5","publisher":"Associação Brasileira de Psiquiatria","id":"76bf86c0-ac38-361c-9a9c-2fa053c6fb62","created":"2019-06-23T11:24:23.770Z","accessed":"2019-06-18","file_attached":false,"profile_id":"38c6dbcb-2394-3f18-9217-58d777c08c69","group_id":"d9389c6c-8ab5-3b8b-86ed-33db09ca0198","last_modified":"2019-06-23T11:24:23.770Z","tags":"Disc:Pharmacology,OA","read":false,"starred":false,"authored":false,"confirmed":false,"hidden":false,"private_publication":false,"abstract":"Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a dissociative anesthetic with sedative and analgesic effects that was developed in the 1960s for human and veterinary medicine. More recently, ketamine has been used to treat severe, refractory depression when pharmacotherapy and electroconvulsive therapy are not effective.1,2 In addition, ketamine is also consumed as drug of abuse, potentially leading to serious and irreversible complications.","bibtype":"article","author":"Ramos, Sergio de P. and Zambonato, Tatiana K. and Graziottin, Túlio M. and Ramos, Sergio de P. and Zambonato, Tatiana K. and Graziottin, Túlio M.","journal":"Brazilian Journal of Psychiatry","number":"3","bibtex":"@article{\n title = {Reduced functional bladder capacity associated with ketamine use},\n type = {article},\n year = {2019},\n identifiers = {[object Object]},\n pages = {270-271},\n volume = {41},\n websites = {http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462019000300270&tlng=en},\n month = {5},\n publisher = {Associação Brasileira de Psiquiatria},\n id = {76bf86c0-ac38-361c-9a9c-2fa053c6fb62},\n created = {2019-06-23T11:24:23.770Z},\n accessed = {2019-06-18},\n file_attached = {false},\n profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},\n group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},\n last_modified = {2019-06-23T11:24:23.770Z},\n tags = {Disc:Pharmacology,OA},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {false},\n hidden = {false},\n private_publication = {false},\n abstract = {Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a dissociative anesthetic with sedative and analgesic effects that was developed in the 1960s for human and veterinary medicine. More recently, ketamine has been used to treat severe, refractory depression when pharmacotherapy and electroconvulsive therapy are not effective.1,2 In addition, ketamine is also consumed as drug of abuse, potentially leading to serious and irreversible complications.},\n bibtype = {article},\n author = {Ramos, Sergio de P. and Zambonato, Tatiana K. and Graziottin, Túlio M. and Ramos, Sergio de P. and Zambonato, Tatiana K. and Graziottin, Túlio M.},\n journal = {Brazilian Journal of Psychiatry},\n number = {3}\n}","author_short":["Ramos, S., d., P.","Zambonato, T., K.","Graziottin, T., M.","Ramos, S., d., P.","Zambonato, T., K.","Graziottin, T., M."],"urls":{"Website":"http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462019000300270&tlng=en"},"bibbaseid":"ramos-zambonato-graziottin-ramos-zambonato-graziottin-reducedfunctionalbladdercapacityassociatedwithketamineuse-2019","role":"author","downloads":0},"bibtype":"article","creationDate":"2019-06-25T07:20:20.779Z","downloads":0,"keywords":[],"search_terms":["reduced","functional","bladder","capacity","associated","ketamine","use","ramos","zambonato","graziottin","ramos","zambonato","graziottin"],"title":"Reduced functional bladder capacity associated with ketamine use","year":2019}